✦ LIBER ✦

Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research

✍ Scribed by MartÃn, Patricia GÃ¡lvez; Martinez, Adolfina Ruiz; Lara, VisitaciÃ³n Gallardo; Naveros, Beatriz Clares

Book ID: 120355891
Publisher: Springer
Year: 2012
Tongue: English
Weight: 432 KB
Volume: 14
Category: Article
ISSN: 0372-8722
DOI: 10.1007/s10238-012-0213-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Development of Advanced Therapy

Clinical Development of Advanced Therapy Medicinal Products in Europe: Evidence That Regulators Must Be Proactive

✍ Maciulaitis, Romaldas; D’Apote, Lucia; Buchanan, Andrew; Pioppo, Laura; Schneide 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 508 KB

Regulatory Considerations for Novel Gene

Regulatory Considerations for Novel Gene Therapy Products: A Review of the Process Leading to the First Clinical Lentiviral Vector

✍ Manilla, Peter; Rebello, Tessio; Afable, Cathleen; Lu, Xiaobin; Slepushkin, Vlad 📂 Article 📅 2005 🏛 Mary Ann Liebert 🌐 English ⚖ 167 KB

Development of a cell-based medicinal pr

Development of a cell-based medicinal product: regulatory structures in the European Union

✍ Gálvez, Patricia (author);Clares, Beatriz (author);Hmadcha, Abdelkrim (author);R 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 197 KB

Development of a cell-based medicinal pr

Development of a cell-based medicinal product: regulatory structures in the European Union

✍ Gálvez, Patricia (author);Clares, Beatriz (author);Hmadcha, Abdelkrim (author);R 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 197 KB

Mesenchymal Stem Cell Therapy || Regulat

Mesenchymal Stem Cell Therapy || Regulatory Considerations Applicable to Manufacturing of Human Placenta-Derived Mesenchymal Stromal Cells (MSC) Used in Clinical Trials in Australia and Comparison to USA and European Regulatory Frameworks

✍ Chase, Lucas G.; Vemuri, Mohan C. 📂 Article 📅 2012 🏛 Humana Press 🌐 English ⚖ 554 KB

Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for th

Factors affecting the turnaround time fo

Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study

✍ Sara Richman; Adrian P. Gee; David H. McKenna; Jay H. Traverse; Timothy D. Henry 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 442 KB